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Osamu Yokosuka, MD32, Chandan Kumar Kedarisetty, DM33, Priyanka Jain, PhD2, Puja Bhatia, MSc2 and Shiv K. Sarin, DM2
for the APASL ACLF working party
OBJECTIVES: Acute insults from viruses, infections, or alcohol are established causes of decompensation leading to
acute-on-chronic liver failure (ACLF). Information regarding drugs as triggers of ACLF is lacking. We
examined data regarding drugs producing ACLF and analyzed clinical features, laboratory
characteristics, outcome, and predictors of mortality in patients with drug-induced ACLF.
METHODS: We identifieddrugsasprecipitants ofACLFamongprospectivecohort ofpatientswithACLF fromtheAsian
Pacific Association of Study of Liver (APASL) ACLF Research Consortium (AARC) database. Drugs were
considered precipitants after exclusion of known causes together with a temporal association between
exposure and decompensation. Outcome was defined as death from decompensation.
RESULTS: Of the 3,132 patients with ACLF, drugs were implicated as a cause in 329 (10.5%, mean age 47 years,
65% men) and other nondrug causes in 2,803 (89.5%) (group B). Complementary and alternative
medications (71.7%) were the commonest insult, followed by combination antituberculosis therapy
drugs (27.3%). Alcoholic liver disease (28.6%), cryptogenic liver disease (25.5%), and non-alcoholic
steatohepatitis (NASH) (16.7%) were common causes of underlying liver diseases. Patients with drug-
inducedACLFhad jaundice (100%), ascites (88%), encephalopathy (46.5%), highModel for End-Stage
Liver Disease (MELD) (30.2), and Child-Turcotte-Pugh score (12.1). The overall 90-day mortality was
higher in drug-induced (46.5%) than in non–drug-induced ACLF (38.8%) (P5 0.007). The Cox
regression model identified arterial lactate (P < 0.001) and total bilirubin (P5 0.008) as predictors of
mortality.
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DISCUSSION: Drugs are important identifiable causes of ACLF in Asia-Pacific countries, predominantly from
complementary and alternative medications, followed by antituberculosis drugs. Encephalopathy,
bilirubin, blood urea, lactate, and international normalized ratio (INR) predictmortality in drug-induced
ACLF.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/A162
Am J Gastroenterol 2019;114:929–937. https://doi.org/10.14309/ajg.0000000000000201
INTRODUCTION
Patients with preexisting chronic liver disease (CLD) are
uniquely susceptible to develop liver failure from acute liver
injury (1,2). Acute liver injury may occur from alcohol (3,4) and
viruses such as hepatitis A, B, or E (5,6). Other precipitants
include drugs and toxins. Often precipitating insults cannot be
identiﬁed (7). Furthermore, CLD by itself is a risk factor for
developing infections such as tuberculosis (8,9), cellulitis, or
spontaneous bacterial peritonitis, which can inﬂuence outcome.
Indeed, some drugs such as combination antituberculosis drugs
used in the setting of CLD can negatively impact outcome.
Although, typically, the presence of underlying CLD does
not increase the overall susceptibility of drug-induced liver
injury (DILI), with certain exceptions that are stated below,
recovery from DILI is less likely, given the reduced hepatic
functional reserves and capacity for adaptation (10,11). Al-
though most drugs are safely tolerated in the setting of CLD,
recent work suggests that individuals with CLD may be at an
increased risk of developing hepatotoxicity at least to certain
drugs (12). Often, several factors may act in concert to increase
the risk of liver injury. For example, in patients with CLD or
cirrhosis, CYP 450 enzymes are diﬀerentially aﬀected (13).
Furthermore, mitochondrial dysfunction, portosystemic
shunting, and alteration of protein binding may modify the
pharmacokinetic and pharmacodynamic characteristics of
drugs (13,14), resulting in increased exposure to drug levels or
their metabolites and reduced clearance. Recent work from the
drug-induced liver injury network from United States has
demonstrated that patients with preexisting liver disease had
a higher risk of death fromDILI (16%) than those without (5%)
(15). Although most drugs are safe in cirrhosis, drugs that have
been implicated as triggering liver injury include antitubercu-
lous drugs, methotrexate, and antiretroviral drugs in HIV/
AIDS-infected individuals, particularly in the setting of un-
derlying hepatitis B or C (10,11,14,16–18).
Moreover, the eﬀect of drugs in patients with cirrhosis is
poorly studied; such patients are commonly excluded from
clinical trials (11). Furthermore, cirrhosis or CLD is highly het-
erogeneous in nature, with diﬀerential contribution of ﬁbrosis,
functioning liver cells, collateral formation, and extent of portal
hypertension, all of which impact outcome (10).
There is growing recognition of the unique characteristics,
natural history, complications, and outcome of patients who
develop acute-on-chronic liver failure (ACLF) (2,19). In-
formation from acute insults such as alcohol, infection, and
organ failure has been reported. However, information re-
garding drugs as acute insults precipitating ACLF is lack-
ing (20).
We aimed to study the proportion of patients with ACLF
precipitated by drugs, the type of drugs, natural history, and
outcome of drug-induced ACLF across a large, multicenter,
internationally representative Asia-Paciﬁc region registry on
ACLF. We compared the characteristics of drug-induced with
non–drug-induced ACLF. We also analyzed the predictors of
mortality and compared the ability of prognostic models to
predict outcome.
PATIENTS AND METHODS
Patients with ACLF secondary to drugs were identiﬁed from the
ACLF Asian Paciﬁc Association of Study of Liver (APASL) Re-
search Consortium (AARC) database. AARC is a multinational
consortium of 29 countries and 52 investigators where patient data
in the age group 17–70 yearswithACLF are collected prospectively
in a predesigned web-based proforma (www.aclf.in). The nodal
point where the data are housed and managed is the Institute of
Liver and Biliary Sciences (ILBS), New Delhi. The Institute Ethical
Committee, i.e., the Institutional Ethics Committee/Institutional
Review Board of ILBS vide letter no F25/5/64/ILBS/AC2013/912,
has approved the study. Informed consent was obtained from
patients, and they are followed up regularly to assess outcome for
up to 3months. Patients were considered to have ACLFwhen they
fulﬁlled established APASL deﬁning criteria: “acute hepatic insult
manifesting as jaundice (total bilirubin .5 mg/dL) and coagul-
opathy (international normalized ratio (INR) .1.5), complicated
within 4 weeks by ascites and/or encephalopathy in a patient with
previously diagnosed or undiagnosed CLD (1,21).
The focus of this study was on drugs as precipitants of acute insults
in the development of ACLF. Because there is no objective conﬁr-
matory laboratory test to establish a diagnosis of DILI and because
patients with CLD may have elevated baseline liver chemistry, the
diagnosis of drug-induced ACLF was largely based on a strong
temporal relationship between exposure to drug(s) and onset of
ACLF together with a rigorous exclusion of competing causes (in-
cluding acute ﬂare from hepatitis B and C) and others as stated
below. Patients had to fulﬁll all 6 criteria as listed below.
1. DILI in patients with preexisting liver disease was deﬁned as
elevation of transaminase levels that were at least 2–3 times
baseline levels or bilirubin levels more than 2 times baseline
(22) but also fulﬁlling criteria for ACLF
2. A strong temporal relationship between exposure to the drug
and recent development of ACLF deﬁned as total bilirubin.5
mg/dL and INR .1.5 together with either ascites and/or
encephalopathy.
3. Patients with increased transaminases alone (regardless of the
fold increase) without the concomitant bilirubin increase of
.5 mg/dL and INR .1.5 and not fulﬁlling clinical criteria
such as ascites and/or encephalopathy were not included.
4. Competing causes such as acute viral hepatitis A and E and
ﬂares from B and C and autoimmune causes were ruled out
after appropriate negative virological and serological tests.
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5. Patients with a history of decompensation such as ascites,
encephalopathy, jaundice, or variceal bleed were excluded.
6. At least 1 imaging study including ultrasonography or
contrast-enhanced computed tomography, which excluded
biliary obstruction or biliary abnormality.
7. Liver biopsy mostly from the transjugular route was
performed whenever indicated for diagnosis and better
characterization of CLD.
The diagnosis of drug-induced ACLFwasmade by the leading
physician at the contributing site. The oﬀending drug that was
considered a likely culprit was stopped immediately. We in-
vestigated the diﬀerent agents/class of drugs causing ACLF, the
baseline admission clinical features and laboratory characteristics
and its impact on 3-month mortality. We also compared the
common groups causing drug-induced ACLF.
Statistical analysis
Categorical variables were presented as proportions, whereas
continuous variables were either presented as mean with s.d. or
median with interquartile range. The chi-square test or Fisher
exact test was used for categorical variables. Normally distributed
continuous variables were compared using the Student t test.
Non-normal continuous variables will be compared using the
Mann-Whitney U test (unpaired data). Prognostic predictors of
death at baseline, day 4, and day 7 were analyzed using Cox
regression in univariate and multivariate analyses. The cumula-
tive probability of survival was depicted using a Kaplan-Meier
graph and was compared using the log-rank test. P , 0.05 was
considered as signiﬁcant. All statistical tests were performed us-
ing SPSS for Windows version 22 (Armonk IBM Corp).
RESULTS
Between April 2009 and April 2018, we analyzed 3,132 patients
with ACLF with complete data including 3-month follow-up.
Drugs were considered triggers of acute insults in 329 cases
constituting 10.5% of cases. Men outnumbered women (64.7%
vs 35.3%). Antituberculosis therapy (ATT) drugs and com-
plementary and alternative medicines (CAMs) constituted
27.3% (n5 90) and 71.7% (n5 236), respectively, whereas the
remaining 1% (n 5 3) were from methotrexate (n 5 2) and
likely anti-epileptic drug (n5 1). The median duration of drug
use in which data were available was 84 days. One hundred
ﬁfty-three patients (46.5%) died, of whom 42 (46.7%), 110
(46.4%), and 1 patient (33%) died of ATT, CAM and non-ATT-
non-CAMdrugs, respectively. Table 1 shows the characteristics
of patients with and without drugs as acute insult including
disease severity scores. Patients with drug-induced ACLF were
more likely to be women (52.3%) compared with 28.5% in
nondrug causes of ACLF (Table 1). Table 2 illustrates the dif-
ferences between survivors and nonsurvivors in the drug group.
Nonsurvivors were signiﬁcantly exposed to CAM and ATT drugs
and demonstrated a higher proportion of encephalopathy, including
worse indexes of liver function (bilirubin and INR), serum creati-
nine, and Model for End-Stage Liver Disease (MELD), APASL,
ACLF Research Consortium (AARC), and other severity scores.
Causes of underlying CLD
The causes of underlying liver diseases were as follows: alcohol-
associated disease (28.6%; n 5 94), cryptogenic liver disease
(25.5%; n 5 84), hepatitis B–related disease (17.3%; n 5 57),
nonalcoholic steatohepatitis (16.7%; n 5 55), autoimmune hep-
atitis (5.5%; n5 10), hepatitis C virus (3.3%; n5 11), and others
(3%; n5 10).
Liver biopsy was performed in 532/3,132 (17%) in the ACLF
cohort. Eighty-nine of 329 cases (27.05%) of the ACLF-DILI
underwent liver biopsy. Histological conﬁrmation of cirrhosis
was noted in 76/89 cases (85.39%) of ACLF from drugs including
19 patients who received anti-TB drugs.
Comparison between ATT drugs and CAMs
Because ATT drugs and CAMs constituted 99% of drugs as
triggers for ACLF, we compared the characteristics between ATT
drugs andCAMs, which is depicted in Table 3. Except for a female
preponderance in the ATT-DILI group, others including liver
biochemistry and liver disease severity scores were similar.
Mortality was also similar (46%). The overall median survival
time was 23.5 days from admission (range 12.6–34.7 days), which
was shorter for CAMs compared with ATT drugs (22 vs 31 days).
Characteristics between survivors and nonsurvivors
The presence of encephalopathy is an indicator of poor survival.
Total bilirubin, INR, serum creatinine, and lactate were signiﬁ-
cantly elevated in nonsurvivors (Table 2). All liver disease severity
scores were signiﬁcantly elevated in nonsurvivors. The total
leukocyte count, a marker of inﬂammation or infection, was also
highly predictive of mortality. Of note, transaminase levels were
not signiﬁcant. Underlying liver disease also did not contribute
toward mortality. The mean body mass index between survivors
(24.8 6 4.1) and nonsurvivors (24.4 6 4.9) was not signiﬁcant
(P5 0.6).
Multivariate analysis. Table 4 shows the dynamic model from
baseline to day 7. Lactate (hazard ratio 1.6–4) was consistently
a predictor of mortality from baseline to day 7, whereas bilirubin
was the other indicator of mortality (hazard ratios 1 and 2.4 at
baseline and 1 week, respectively).
Predictors of 90-day mortality. Predictors of mortality from
baseline variables in patients with ACLF-DILI are shown in
Table 5. Encephalopathy, INR, bilirubin, and lactate were sig-
niﬁcant. The area under receiver operating characteristic
(AUROC) with sensitivity and speciﬁcity is shown in Figure 1.
We analyzed liver disease severity models and found the
AARCModel andMELD scores are better indicators of mortality
with an ROC of 0.75 and 0.74, respectively (Figure 2).
DISCUSSION
The results from a large multicenter registry showed drugs
constituting 10.5% of acute insults in patients presenting with
ACLF. Furthermore, overall mortality from drug-induced
ACLF was 46.5%, which was signiﬁcantly higher than 38.8%
from nondrug causes (P5 0.007). However, mortality between
anti-TB drugs and CAMs was similar (46%). ACLF from drugs
did not have any speciﬁc characterization, except the pro-
portion of females was 53.3% compared with 28.5% in
non–drug-induced ACLF (Table 1), which is in line with
studies on DILI (15,23) together with higher mortality across
many DILI registries (15,23,24). Of note, our cohort included
only patients with severe liver disease as any increase in ami-
notransferase without a concomitant increase in bilirubin
levels of .5 mg/dL and INR . 1.5 were excluded.
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Table 1. Comparison of the baseline parameters among ACLF cases with acute insult from drugs vs others
Variable
ACLF (drugs) ACLF (nondrugs)
P value
Group A Group B
n 5 329 n5 2,803
Age (yr) 46.9 6 13.72 44.236 12.07 0.001
Sex, male 213 (64.7%) 2,446 (87.5%) ,0.001
Etiology of acute insult (n, %)
Antituberculosis drugs 90 (27.4)
Complementary, Ayurvedic, and HDS 187 (56.8)
Non-ATT, non-CAM, non-HDS 52 (15.8)
Etiology of chronic disease (n, %)
Alcoholic disease 92 (28) 1,454 (56.6) ,0.001
Cryptogenic disease 236 (72) 1,115 (43.4) ,0.001
Clinical presentation (n, %)
Jaundice 329 (100) 2,803 (100) NA
Ascites 289 (88.4) 2,263 (88.5) 0.779
Encephalopathy 145 (46.5) 1,094 (45.1) 0.672
Laboratory parameters
Hemoglobin (g/dL) 10.916 2.34 10.52 6 2.26 0.002
WBC (103/dL) 10.7 (1.6–44.3) 11.3 (1–201) 0.045
Platelets (103/dL) 126 (10–495) 129 (2.16–803) 0.558
PT-INR 2.29 (1.5–11.14) 2.13 (1.5–25.3) ,0.001
Total bilirubin (mg/dL) 21.546 8.99 19.94 6 9.74 0.002
Direct bilirubin (mg/dL) 12.876 6.18 12.42 6 6.56 0.223
AST (IU/L) 163 (16.8–6,980) 147 (2.5–7,552) 0.019
ALT (IU/L) 86 (1.28–2,770) 60 (0.08–4,986) ,0.001
ALP (IU/L) 125 (27–1,132) 119 (4–1,590) 0.246
GGT (IU/L) 53 (9–634) 76 (1.8–1,536) ,0.001
Albumin (g/dL) 2.26 6 0.61 2.37 6 0.65 0.004
Urea (mg/dL) 31 (1.9–352.1) 31.62 (0.2–343) 0.680
Serum creatinine (mg/dL) 0.87 (0.01–9.22) 1 (0–15.28) 0.003
Serum Na (meq/l) 131.686 7.6 131.2 6 7.6 0.32
Lactate (mg/dL) 2 (0.1–22) 1.9 (0.1–44.1) 0.395
Disease severity score
CTP 12.016 1.49 11.96 6 1.44 0.373
MELD score 30.226 7.17 28.86 6 7.08 ,0.001
APACHE score 15.636 6.16 16.49 6 6.89 0.154
CLIF-SOFA 11.626 2.55 11.51 6 2.75 0.445
AARC score 10.19 6 2.2 10.01 6 2.1 0.25
SOFA 9.23 6 3.35 9.02 6 3.12 0.276
Mortality at 90 d (n, %) 153 (46.5) 1,088 (38.8) 0.007
AARC,APASLACLFResearchConsortium; ACLF, acute-on-chronic liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APACHE,Acute Physiology and
Chronic Health Evaluation; AST, aspartate aminotransferase; ATT, antituberculosis therapy; CAM, complementary and alternative medication; CLIF-SOFA, Chronic Liver
Failure- Sequential Organ Failure Assessment; CTP: Child-Turcotte-Pugh; GGT, Gamma glutamyl transferase; HDS, herbal and dietary supplement; HE, hepatic
encephalopathy; INR, International Normalized Ratio; MELD, Model for End-Stage Liver Disease; SOFA, Sequential Organ Failure Assessment; ST, aspartate
aminotransferase; TLC, total leucocyte count; WBC, white blood count.
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It is commonly believed that patients with cirrhosis are not
at a higher risk of DILI (10), but complications fromDILI may
result in a less favorable outcome because of diminished he-
patic functional reserves and decreased ability to mount an
adaptive response. The high mortality of 46.6% is indicative of
this fact and is supported by the 16.5%mortality in individuals
with preexisting liver disease from the DILIN series compared
with 5% in those without CLD, highlighting the real and subtle
Table 2. Baseline characteristics between survivors and nonsurvivors in the ACLF-DILI cohort
Variable
Survivors Nonsurvivors
P valuen 5 176 (53.5) n 5 153 (46.5)
Age (yr) 45.52 6 13.51 48.58 6 13.83 0.065
Sex, male 118 (67%) 95 (62.1%) 0.357
Etiology of acute insult (n, %) 0.002
Antituberculous drugs 48 (27.3) 42 (27.5)
Complementary, Ayurveda, and HDS 89 (50.6) 98 (64.1)
Non-ATT, non-CAM, non-HDS 39 (22.2) 13 (8.5)
Etiology of chronic disease (n, %) 0.269
Alcoholic disease 54 (30.7) 38 (25)
Cryptogenic disease 122 (69.3) 114 (75)
Clinical presentation (n, %)
Jaundice 176 (100) 153 (100) NA
Ascites 137 (90.1) 152 (86.9) 0.390
Encephalopathy 60 (36.6) 85 (57.4) ,0.001
Laboratory parameters
Hemoglobin (g/dL) 11.03 6 2.23 10.78 6 2.47 0.299
WBC (103/dL) 9.65 (1.6–44.3) 11.6 (3.65–41.5) 0.004
Platelets (103/dL) 130 (15–495) 122.5 (10–474) 0.65
INR 2.39 6 0.98 3.18 6 1.55 ,0.00
Total bilirubin (mg/dL) 19.50 6 8.61 23.87 6 8.87 ,0.001
Direct bilirubin (mg/dL) 12.0 6 5.88 13.88 6 6.38 0.20
AST (IU/L) 159 (21–2,947) 173 (16.8–6,980) 0.171
ALT (IU/L) 85 (1.29–2,307) 89 (1.55–2,770) 0.732
ALP (IU/L) 130 (27–1,132) 112 (30–781) 0.049
GGT (IU/L) 54.5 (9–439) 49 (10–634) 0.503
Albumin (g/dL) 2.26 6 0.62 2.27 6 0.59 0.613
Urea (mg/dL) 27.74 (2.7–296) 35 (1.9–352.1) 0.008
Serum creatinine (mg/dL) 0.8 (0.01–9.22) 1.03 (0.15–8.87) 0.003
Serum Na (meq/L) 131.76 7.8 131.66 7.5 0.96
Lactate (mg/dL) 1.9 (0.6–22) 2.1 (0.1–21.9) 0.020
Disease severity score
CTP 11.75 6 1.32 12.30 6 1.62 0.020
MELD score 27.51 6 6.40 33.29 6 6.76 ,0.001
APACHE score 14.33 6 5.27 16.76 6 6.65 0.038
AARC score 10.98 6 1.88 9.27 6 2.08 ,0.001
CLIF-SOFA 10.91 6 2.31 12.26 6 2.59 ,0.001
SOFA 8.33 6 2.61 10.12 6 3.76 ,0.001
AARC,APASLACLFResearchConsortium; ACLF, acute-on-chronic liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APACHE, Acute Physiology and
Chronic Health Evaluation; AST, aspartate aminotransferase; ATT, antituberculosis therapy; CAM, complementary and alternative medication; CLIF-SOFA, Chronic Liver
Failure- Sequential Organ Failure Assessment; CTP: Child-Turcotte-Pugh; GGT, Gamma glutamyl transferase; HDS, herbal and dietary supplement; HE, hepatic
encephalopathy; INR, International Normalized Ratio; MELD, Model for End-Stage Liver Disease; SOFA, Sequential Organ Failure Assessment; ST, aspartate
aminotransferase; TLC, total leucocyte count; WBC, white blood count.
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Table 3. Comparison between ACLF-DILI cases due to ATT drugs and CAMs
Variable
ATT drugs CAMs
P valueN 5 90 N 5 236
Age (yr) 46.9 6 14.1 46.9 6 13.6 1.0
Sex, male 42 (46.7%) 170 (72.0%) ,0.001
Clinical presentation (n, %)
Jaundice 90 (100%) 236 (100%)
Ascites 79 (88.8%) 194 (87.4%) 0.74
Encephalopathy 44 (50.0%) 101 (45.7%) 0.49
Laboratory parameters
Hemoglobin (g/dL) 10.5 6 2.05 11.05 6 2.4 0.06
WBC (103/dL) 9.6 (1.6,35.2) 11.14 (2.4,44.3) 0.02
Platelets (103/dL) 122 (10,449) 26 (15,495) 0.22
INR 2.3 (1.5,11.14) 2.24 (1.5,7.7) 0.81
Total bilirubin (mg/dL) 20.5 6 8.6 21.9 6 9.1 0.18
Direct bilirubin (mg/dL) 12.0 6 5.7 13.2 6 6.4 0.11
AST (IU/L) 136.5 (37,2947) 170 (16.8,6980) 0.12
ALT (IU/L) 76.5 (16,2419) 91 (1.29,2770) 0.55
ALP (IU/L) 132 (27,781) 121 (39,1132) 0.32
GGT (IU/L) 26.75 (2.7,296) 34 (1.9,352.1) 0.30
Albumin (g/dL) 2.29 6 0.62 2.26 6 0.61 0.71
Urea (mg/dL) 26.75 (2.7,296) 34 (1.9,352.1) 0.006
Serum creatinine (mg/dL) 0.81 (0.15,9.2) 0.91 (0.01,7.4) 0.11
Serum Na (meq/L) 132.56 8.30 131.4 6 7.4 0.26
Lactate (mg/dL) 2.3 (1.0,21.9) 1.9 (0.1,22) 0.02
Disease severity score
CTP 12.0 6 1.57 12.026 1.47 0.70
MELD score 29.9 6 7.18 30.386 7.21 0.61
APACHE score 14.6 6 5.8 16.1 6 6.30 0.17
CLIF-SOFA 11.6 6 2.26 11.6 6 2.67 0.95
AARC score 10.216 2.14 10.2 6 2.16 0.81
SOFA 9.06 3.6 9.46 3.3 0.52
90-d mortality (n, %) 42 (46.7%) 110 (46.6%) 0.99
AARC, APASL ACLF Research Consortium; ACLF, acute-on-chronic liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APACHE, Acute Physiology and Chronic
HealthEvaluation;AST,aspartateaminotransferase;ATT,antituberculosis therapy;CAM,complementaryandalternativemedication;CLIF-SOFA,ChronicLiverFailure-SequentialOrgan
Failure Assessment; CTP: Child-Turcotte-Pugh; GGT, Gamma glutamyl transferase; HDS, herbal and dietary supplement; HE, hepatic encephalopathy; INR, International Normalized
Ratio; MELD, Model for End-Stage Liver Disease; SOFA, Sequential Organ Failure Assessment; ST, aspartate aminotransferase; TLC, total leucocyte count; WBC, white blood count.
Table 4. Factors influencing mortality dynamically in drug-induced cases by multivariate Cox regression analysis
Parameter
Baseline Day 4 Day 7
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Urea 1.373 (1.097,1.716) 0.006 1.378 (1.044, 1.818) 0.024
Lactate 1.678 (1.203,2.342) 0.002 4.419 (3.047, 6.407) ,0.001 4.035 (2.715, 5.997) ,0.001
INR 4.028 (2.401,6.759) ,0.001
HE 1.566 (1.051,2.333) 0.027
Total bilirubin 1.035 (1.012,1.058) 0.002 2.441 (1.265, 4.711) 0.008
CI, confidence interval; HE, hepatic encephalopathy; HR, hazard ratio; INR: International Normalized Ratio.
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risks of liver injury and mortality in such patients (15). Tra-
ditional markers of liver injury such as elevated AST and ALT
may not be reliable signals in individuals with preexisting liver
disease (24). Others such as elevated bilirubin and coagul-
opathy may be more appropriate and indicative of severe liver
injury (24). This is reﬂected in our series in which trans-
aminase elevation was only 2- to 4-fold, whereas there was
a marked increase in bilirubin and INR. The mild elevation of
transaminase, but marked elevation of bilirubin, has been
reported before and may be a feature speciﬁc to ATT drugs or
CAMs (25). Indeed, even in patients without preexisting liver
disease, the modest increase in transaminase in relation to
bilirubin has been described in antituberculosis therapy
DILI (26).
Patients with cirrhosis are a heterogeneous group with
variable levels of ﬁbrosis, inﬂammation, and portal
hypertension, all of which play a diﬀerential role in the me-
tabolism of drugs. Patients with cirrhosis have altered phar-
macokinetic and pharmacodynamic proﬁle (10). Although
there are no speciﬁc guidelines for administering drugs in
patients with preexisting liver disease, guidelines for antitu-
berculous drugs from diﬀerent societies have been in place;
these are often not clear and are variably followed (27). The
commonest underlying liver disease was alcohol-associated
liver disease. That a quarter of patients in our series had
cryptogenic liver disease is not surprising, given the in-
creasing incidence of obesity and diabetes mellitus in the
population. Because our online data do not capture in-
formation on the presence or absence of diabetes, we are
unable to provide this information. Studies have shown that
perturbations in metabolism in fatty liver cells increase the
Table 5. Predictor of 90-d mortality in patients with ACLF-DILI from baseline variables
Univariate Multivariate
Parameter HR 95% CI P HR 95% CI P
Age 1.014 1.002, 1.026 0.022
TLC 1.606 1.205, 2.141 0.001
INR 4.286 2.966, 6,193 ,0.001 4.028 2.401, 6.759 ,0.001
Urea 1.370 1.135, 1,655 0.001 1.373 1.097, 1.716 0.006
Creatinine 1.505 1.249, 1.813 ,0.001
Total bilirubin 1.039 1.02, 1.057 ,0.001 1.035 1.012, 1.058 0.002
Lactate 2.065 1.515, 2.815 ,0.001 1.678 1.203, 2.342 0.002
HE 2.335 1.68, 3.24 ,0.001 1.566 1.051, 2.333 0.027
ACLF, acute-on-chronic liver failure; CI, confidence interval; DILI, drug-induced liver injury; HE, hepatic encephalopathy; HR, hazard ratio; INR, International Normalized
Ratio; TLC, total leucocyte count.
Figure 1. AUROC of the multivariate Cox regression model. Figure 2. AUROC of all severity scores.
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risk of liver injury as exempliﬁed by obesity being a risk factor
for liver injury (14,16,28). Body mass index was 24.4 6 4.8 in
survivors compared with 24.8 6 4.2 in nonsurvivors and was
not signiﬁcant (P 5 0.63) in our series. Patients with CLD
taking combination ATT drugs may be particularly at risk,
given the large dose of each of the antituberculosis drugs to-
gether with lipophilicity of these drugs (29). Furthermore, 6
Asian countries constitute more than 60% of the world’s TB
population, with India itself contributing to nearly a fourth
(World Health Organization report 2017).
The fact that complementary and alternative drugs rank
ﬁrst is also not surprising. The use of CAMs including herbal
and dietary substances is ubiquitous and growing, andmany of
these compounds often contain multiple ingredients that are
detrimental to the liver (30,31). Traditional medicines are used
for all kinds of diseases in many Eastern countries and if often
integrated into the health care of countries such as China,
South Korea, Singapore, and India. More than 80% of the
population in these countries is exposed to complementary
medicines. Causality assessment is challenging in such
instances, particularly when patients are exposed to multi-
ingredient products, which is very common in traditional
medicines including the AYUSH group of drugs. Lax regula-
tion in production of these compounds and questionable safety
and eﬃcacy records places patients with cirrhosis at an in-
creased risk of developing liver injury that leads to de-
compensation. The high mortality in patients with chronic
disease from the DILIN series is in line with our results and
attests to the caution that needs to be exercised in such
patients (30).
There are limitations to our study. We selected only patients
who fulﬁlled criteria for ACLF, which include bilirubin levels of
.5 mg/dL and INR.1.5. Thus, we included only patients with
relatively severe disease (ACLF) because those with only ele-
vation of aminotransferase regardless of the fold increase and/or
bilirubin levels ,5 mg/dL were excluded. Furthermore, those
without concomitant coagulopathy, ascites, or encephalopathy
were excluded. A further limitation is the challenge of causality
assessment in patients with preexisting liver disease, which has
been highlighted in a recent review (22). Liver chemistry
monitoring may be diﬃcult to interpret in the presence of
underlying CLD, especially when baseline tests are altered.
Care was taken to exclude competing causes by local principal
investigators. Expert opinion for causality assessment has
been undertaken before, particularly in large population-
based studies (32,33). We are also aware about the hetero-
geneity of care among the large number of contributing
centers from diﬀerent countries, with many lacking liver
transplantation facility. Ironically, in such centers, the nat-
ural history of the disease could be observed. Attribution of
antituberculosis drugs and complementary drugs as precip-
itants of ACLF was straightforward. However, identifying the
individual constituents of CAMs was not possible. CAM,
which includes traditional medicines including AYUSH
(Ayurveda, Unani, Siddha, and Homeopathy), very often
consists of undeclared constituents in the form of powders,
pastes, and tablets (See Figure 1, Supplemental Digital Con-
tent, http://links.lww.com/AJG/A162) Very often, a single
tablet consists of a number of ingredients in 1 instance up to
49. Furthermore, our online case record does not have pro-
vision to capture individual drug or component details. An
example of multi-ingredient sample is shown in Supplemental
Digital Content, Figure 1, http://links.lww.com/AJG/A162. Our
study highlights the challenges faced with regard to causality
assessment in patients with preexisting liver disease and the
eﬀort that is needed to ﬁnd alternatives to RUCAM (Roussell
Uclaf Causality AssessmentMethod). Many of the domains in
RUCAM including the increase in transaminase may not be
pertinent to patients with cirrhosis; patients with cirrhosis
often do not mount a massive increase in transaminase; in-
stead, increased bilirubin and/or coagulopathy may be an
initial sign of injury as acknowledged in previous reports
(24,30). This can be complemented with other synthetic
markers such as albumin and INR. The role of cytokine
proﬁles, microRNA-122 and HMGB-1, when these become
available oﬀers hope but needs to be validated (34), and tests
of quantitative liver function that can detect functional im-
pairment and help identify high-risk groups for de-
compensation are urgently needed (35).
In conclusion, CAMs and anti-TB medications constitute
about a tenth of all causes of ACLF with a substantial mortality
in nearly half of patients with drug-induced ACLF. Alcoholic
liver disease, cryptogenic liver disease, and non-alcoholic
steatohepatitis (NASH) constitute a majority of common
causes of underlying liver disease. Bilirubin, INR, lactate and
encephalopathy or AARC or MELD scores are more reliable
signals of mortality in a setting of CLD.
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Study Highlights
WHAT IS KNOWN
3 Drug-induced liver injury (DILI) causing ACLF is rare, and the
proportion of ACLF secondary to DILI is unknown.
3 Patients with CLD take complimentary and alternative
medicine assuming it to be safe and healthy and without side
effects.
3 Mortality from ACLF is high.
WHAT IS NEW HERE
3 Drug-induced ACLF constitutes more than 10% of causes of
ACLF in the Asia-Pacific region.
3 CAMs followed by antituberculosis drugs are the top 2
commonest causes of drug-induced ACLF.
3 Mortality from drug-induced ACLF is high (46.6%) compared
with nondrug causes (38.8%) of ACLF.
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